Scholarlink

Summary <p>Chronic kidney disease patients face increased osteoporosis and fracture risk. High-potency statins were associated with lower osteoporosis incidence but also with higher long-term fracture incidence in this observational study. These findings highlight the need for tailored statin use and proactive fracture monitoring in CKD populations for optimal bone health management.</p> Purpose <p>Chronic kidney disease (CKD) affects approximately 850 million people worldwide and is associated with increased risks of cardiovascular events and fractures. The differential effects of statin potency on bone health in CKD patients remain incompletely understood.</p> Methods <p>This retrospective cohort study used the TriNetX US Collaborative Network to identify adults with CKD stages 3 or 4 initiating statin therapy, categorized into high-potency (atorvastatin 40–80&#xa0;mg, rosuvastatin 20–40&#xa0;mg) and low-potency groups. After 1:1 propensity score matching, three primary outcomes were evaluated: new osteoporosis diagnosis, anti-osteoporotic medication initiation, and incident fractures, assessed at 3–12&#xa0;months and beyond 12&#xa0;months. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using Cox and competing risk regression models.</p> Results <p>Among 873,180 matched patients, high-potency statins were associated with a 20.0% reduction in osteoporosis diagnosis (HR 0.80; 95% CI 0.78–0.82) and 24.9% fewer anti-osteoporotic medication prescriptions (HR 0.75; 95% CI 0.73–0.78) during 3–12&#xa0;months, with associations persisting beyond 12&#xa0;months. Fracture risk did not differ at 3–12&#xa0;months (HR 0.99; 95% CI 0.96–1.02); but increased beyond 12&#xa0;months (HR 1.13; 95% CI 1.11–1.15).</p> Conclusions <p>High-potency statins are associated with lower osteoporosis diagnosis rates and fewer anti-osteoporotic medication prescriptions in CKD stages 3 and 4. The increased long-term fracture risk may reflect a diagnostic gap wherein lower osteoporosis detection contributes to under-treatment of bone fragility. Prospective randomized controlled trials with bone-specific endpoints are warranted to confirm these findings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

High-potency statins are associated with reduced osteoporosis but increased fracture risk in CKD patients: a multi-center retrospective study

  • 期刊论文

  • 发表日期：

    2026年4月15日

查看全文
  • Ping-Hsun Wu,
  • Yi-Ting Lin,
  • Jian-Chih Chen,
  • Sung-Yen Lin,
  • Li-Ting Kao,
  • Yu-Ting Huang,
  • Pei-Shan Ho,
  • Chung-Hwan Chen,
  • Tien-Ching Lee

摘要

Summary

Chronic kidney disease patients face increased osteoporosis and fracture risk. High-potency statins were associated with lower osteoporosis incidence but also with higher long-term fracture incidence in this observational study. These findings highlight the need for tailored statin use and proactive fracture monitoring in CKD populations for optimal bone health management.

Purpose

Chronic kidney disease (CKD) affects approximately 850 million people worldwide and is associated with increased risks of cardiovascular events and fractures. The differential effects of statin potency on bone health in CKD patients remain incompletely understood.

Methods

This retrospective cohort study used the TriNetX US Collaborative Network to identify adults with CKD stages 3 or 4 initiating statin therapy, categorized into high-potency (atorvastatin 40–80 mg, rosuvastatin 20–40 mg) and low-potency groups. After 1:1 propensity score matching, three primary outcomes were evaluated: new osteoporosis diagnosis, anti-osteoporotic medication initiation, and incident fractures, assessed at 3–12 months and beyond 12 months. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using Cox and competing risk regression models.

Results

Among 873,180 matched patients, high-potency statins were associated with a 20.0% reduction in osteoporosis diagnosis (HR 0.80; 95% CI 0.78–0.82) and 24.9% fewer anti-osteoporotic medication prescriptions (HR 0.75; 95% CI 0.73–0.78) during 3–12 months, with associations persisting beyond 12 months. Fracture risk did not differ at 3–12 months (HR 0.99; 95% CI 0.96–1.02); but increased beyond 12 months (HR 1.13; 95% CI 1.11–1.15).

Conclusions

High-potency statins are associated with lower osteoporosis diagnosis rates and fewer anti-osteoporotic medication prescriptions in CKD stages 3 and 4. The increased long-term fracture risk may reflect a diagnostic gap wherein lower osteoporosis detection contributes to under-treatment of bone fragility. Prospective randomized controlled trials with bone-specific endpoints are warranted to confirm these findings.